secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001193125-24-076600
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics gets FDA clearance for NeuroStar as first-line adjunct for adolescent MDD (ages 15-21)
--------------------------------------------------------------------------------

- FDA cleared NeuroStar Advanced Therapy as first-line adjunct treatment for major depressive disorder in adolescents aged 15-21.
- Supplemental information posted to Neuronetics IR website on March 25, 2024.
- Expands NeuroStar's indicated population beyond adults to include adolescents with MDD.
- No financial details, revenue guidance, or commercial launch timeline were disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000119312524076600/0001193125-24-076600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000119312524076600/d791913d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-076600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer